The White House’s direct-to-consumer (DTC) platform TrumpRx is steadily expanding its catalog, with the latest GSK and Amgen products joining the collection of medicines offered through the program.
Amgen’s Humira biosimilar Amjevita, migraine drug Aimovig, and cholesterol drug Repatha became available through TrumpRx on Monday. Meanwhile, GSK is offering DTC discounts on some of its Ellipta inhalers and its influenza drug Relenza through its platform.
Amjevita is available to cash-paying patients for $299 per month, an 80% discount from the physician’s list price of $1,484. According to the website, Aimovig and Repatha are discounted by 62% off their respective list prices.
GSK’s Anoro Ellipta comes with a 49% DTC discount. Arnuity Ellipta is 51-54% cheaper than list price through the platform, while Inruise Ellipta’s cash price is 55% cheaper. Relenza’s TrumpRx is priced at $52.90 per month, a 10% discount off the original price of $59.
The new additions bring the total number of drugs offered through TrumpRx to 54.
In addition to Novo Nordisk’s popular GLP-1 drugs Ozempic and Wigovy (including Wigovy’s newest tablet), the DTC portal also features AstraZeneca’s inhaler, EMD Serono’s fertility drug, and many other high-demand medicines.
The website was first announced in September as part of President Trump’s broader effort to impose a “most-favored-nation” (MFN) pricing model for prescription drugs that seeks to link U.S. prices to prices in other countries. In July, the Trump administration issued a letter to 17 of the world’s largest drug companies detailing steps they “must take” to bring U.S. drug prices in line with international benchmark prices, promising harsh consequences if the companies did not comply.
Pfizer was the first to get on the ball, entering into a drug pricing agreement last fall that eased MFN prices for Medicaid products, allowing many drugs to be sold through TrumpRx. Over a dozen other drug companies have since followed suit.
But the agreements have recently drawn the ire of several Senate Democrats, who sent letters to certain participating companies earlier this month asking for clarification on “evidence that these agreements benefit American patients and taxpayers in terms of savings to the Medicaid program.”
TrumpRx was originally scheduled to go live in January, but was delayed to the end of the month, possibly related to antitrust concerns surrounding the website, Brian Reed, a health consultant and president of Reed Strategic, told Politico at the time.
Amgen’s Repatha was one of the few drugs the White House highlighted in its December MFN fact sheet, touting nine new deals with top drug companies and noting that certain drugs, including BMS, Boehringer Ingelheim and Gilead, will soon be available on the DTC portal.
As Euractiv Advocacy Lab reported, earlier this month, Amgen withdrew Repatha from the Danish market, in what could be the country’s first case caused by the US’s most-favored-nation policy.
“Due to significant changes in the market, the current bidding conditions mean that Amgen is no longer able to supply Repatha to Denmark,” a company spokesperson told news outlet Euractic at the time. “The price offered does not adequately reflect the value of this innovative medicine and its continued supply is commercially unsustainable.”
In October, Amgen announced its own Repatha discount through its AmgenNow program, which sells the drug at the same $239 TrumpRx price point.
